Srinivasan Dasarathy1, Mack C Mitchell2, Bruce Barton3, Craig J McClain4, Gyongyi Szabo5, Laura E Nagy6, Svetlana Radaeva7, Arthur J McCullough6. 1. Cleveland Clinic, USA. Electronic address: dasaras@ccf.org. 2. University of Texas at Southwestern University, USA. 3. University of Massachusetts, USA. 4. University of Louisville, USA. 5. Harvard Medical School & Beth Israel Deaconess Medical Center, USA. 6. Cleveland Clinic, USA. 7. National Institute of Alcohol Abuse and Alcoholism, USA.
Abstract
BACKGROUND/AIMS: Despite high mortality of alcohol-associated hepatitis, there has been limited advancement in treatment strategies. Defeat Alcoholic Steatohepatitis (DASH) is a multicenter, randomized, double-blind controlled trial whose primary objective was to evaluate the safety and efficacy of a novel combination of 3 drugs targeting different perturbations in AH. METHODS: Severe AH was diagnosed by liver biopsy or clinical and biochemical criteria and model for end stage liver disease (MELD) score ≥ 20 stratified by MELD scores (20-25 and ≥ 26) and randomized to a combination of an interleukin receptor 1 antagonist, Anakinra(100 mg daily for 14 days) to suppress acute inflammation, pentoxifylline (400 mg three times a day for 28 days) to prevent hepatorenal syndrome, and zinc sulfate (220 mg orally once daily for 6 months) or the standard of care therapy including methylprednisolone 32 mg orally once daily for 28 days. The primary efficacy outcome was the unadjusted log-rank test of the Kaplan-Meier survival estimates for the two treatment groups at 180 days. RESULTS:Between July 2012 to March 2018, 500 subjects with severe AH were screened of which 104 subjects were enrolled with MELD score of 25.6 ± 3.2 (20.0-35.0) in the investigational arm and 25.8 ± 4.5 (20.0-40.0) in the standard of care arm. Causes of screen failures included not meeting eligibility criteria (n = 347), declining to participate (n = 39), and other reasons (n = 10). CONCLUSIONS: Data from the DASH consortium studies will determine if a combination of drugs targeting multiple mechanisms of injury in the severe AH will improve clinical outcomes.
RCT Entities:
BACKGROUND/AIMS: Despite high mortality of alcohol-associated hepatitis, there has been limited advancement in treatment strategies. Defeat Alcoholic Steatohepatitis (DASH) is a multicenter, randomized, double-blind controlled trial whose primary objective was to evaluate the safety and efficacy of a novel combination of 3 drugs targeting different perturbations in AH. METHODS: Severe AH was diagnosed by liver biopsy or clinical and biochemical criteria and model for end stage liver disease (MELD) score ≥ 20 stratified by MELD scores (20-25 and ≥ 26) and randomized to a combination of an interleukin receptor 1 antagonist, Anakinra(100 mg daily for 14 days) to suppress acute inflammation, pentoxifylline (400 mg three times a day for 28 days) to prevent hepatorenal syndrome, and zinc sulfate (220 mg orally once daily for 6 months) or the standard of care therapy including methylprednisolone 32 mg orally once daily for 28 days. The primary efficacy outcome was the unadjusted log-rank test of the Kaplan-Meier survival estimates for the two treatment groups at 180 days. RESULTS: Between July 2012 to March 2018, 500 subjects with severe AH were screened of which 104 subjects were enrolled with MELD score of 25.6 ± 3.2 (20.0-35.0) in the investigational arm and 25.8 ± 4.5 (20.0-40.0) in the standard of care arm. Causes of screen failures included not meeting eligibility criteria (n = 347), declining to participate (n = 39), and other reasons (n = 10). CONCLUSIONS: Data from the DASH consortium studies will determine if a combination of drugs targeting multiple mechanisms of injury in the severe AH will improve clinical outcomes.
Authors: Zhanxiang Zhou; Lipeng Wang; Zhenyuan Song; Jack T Saari; Craig J McClain; Y James Kang Journal: Am J Pathol Date: 2005-06 Impact factor: 4.307
Authors: C L Mendenhall; S Anderson; P Garcia-Pont; S Goldberg; T Kiernan; L B Seeff; M Sorrell; C Tamburro; R Weesner; R Zetterman Journal: N Engl J Med Date: 1984-12-06 Impact factor: 91.245
Authors: Alexandre Louvet; Mark R Thursz; Dong Joon Kim; Julien Labreuche; Stephen R Atkinson; Sandeep Singh Sidhu; John G O'Grady; Evangelos Akriviadis; Emmanouil Sinakos; Robert L Carithers; Marie-José Ramond; Willis C Maddrey; Timothy R Morgan; Alain Duhamel; Philippe Mathurin Journal: Gastroenterology Date: 2018-05-05 Impact factor: 22.682
Authors: Tatsunori Miyata; Xiaoqin Wu; Xiude Fan; Emily Huang; Carlos Sanz-Garcia; Christina K Cajigas-Du Ross; Sanjoy Roychowdhury; Annette Bellar; Megan R McMullen; Jaividhya Dasarathy; Daniela S Allende; Joan Caballeria; Pau Sancho-Bru; Craig J McClain; Mack Mitchell; Arthur J McCullough; Svetlana Radaeva; Bruce Barton; Gyongyi Szabo; Srinivasan Dasarathy; Laura E Nagy Journal: JCI Insight Date: 2021-02-22